Literature DB >> 29759095

Giant left ventricular rhabdomyoma treated successfully with everolimus: case report and review of literature.

Alfonso Martínez-García1, Carolina Michel-Macías2, Guadalupe Cordero-González2, Karla I Escamilla-Sánchez2, Mónica Aguinaga-Ríos3, Alejandra Coronado-Zarco2, Jorge A Cardona-Pérez2.   

Abstract

IntroductionIntracardiac rhabdomyomas can cause severe ventricular dysfunction and outflow tract obstruction.Case reportA term newborn infant with antenatal diagnosis of giant left ventricle rhabdomyoma presented with cardiac failure and duct-dependent systemic circulation after birth. She was treated successfully with everolimus, showing decrease in tumour size and improvement in left ventricular ejection fraction.DiscussionTumour regression rate was 0.32 cm2/day and improved to 0.80 cm2/day with the use of everolimus. Herein we report a newborn with inoperable giant left ventricular cardiac rhabdomyoma and significant regression of the tumour. To our knowledge, this is the largest left ventricular rhabdomyoma reported. A review of the literature was undertaken for comparison.
CONCLUSION: Everolimus has proven to be efficacious in size reduction of cardiac rhabdomyomas in cases when surgical resection is not possible.

Entities:  

Keywords:  Rhabdomyoma; everolimus; newborn; sirolimus

Mesh:

Substances:

Year:  2018        PMID: 29759095     DOI: 10.1017/S1047951118000598

Source DB:  PubMed          Journal:  Cardiol Young        ISSN: 1047-9511            Impact factor:   1.093


  4 in total

1.  Multiple intracardiac benign tumors treated with low-dose everolimus.

Authors:  Meryem Beyazal; Ahmet Özyazıcı; Şule Yeşil
Journal:  Anatol J Cardiol       Date:  2022-02       Impact factor: 1.596

2.  [Importance of heart rabdomioma in pediatric population. A 39 year experience. Case series].

Authors:  Nadia G Chía-Vázquez; Gerardo Fuentes-Ramos; Emilia J Patiño-Bahena; Atziri Guillén-González; Alfonso Buendía-Hernández
Journal:  Arch Cardiol Mex       Date:  2020-12-16

Review 3.  Treatment of Cardiac Rhabdomyomas with mTOR Inhibitors in Children with Tuberous Sclerosis Complex-A Systematic Review.

Authors:  Monika Sugalska; Anna Tomik; Sergiusz Jóźwiak; Bożena Werner
Journal:  Int J Environ Res Public Health       Date:  2021-05-05       Impact factor: 3.390

4.  Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients' Perspectives.

Authors:  Laurent M Willems; Felix Rosenow; Susanne Schubert-Bast; Gerhard Kurlemann; Johann Philipp Zöllner; Thomas Bast; Astrid Bertsche; Ulrich Bettendorf; Daniel Ebrahimi-Fakhari; Janina Grau; Andreas Hahn; Hans Hartmann; Christoph Hertzberg; Frauke Hornemann; Ilka Immisch; Julia Jacobs; Karl Martin Klein; Kerstin A Klotz; Gerhard Kluger; Susanne Knake; Markus Knuf; Klaus Marquard; Thomas Mayer; Sascha Meyer; Hiltrud Muhle; Karen Müller-Schlüter; Felix von Podewils; Susanne Ruf; Matthias Sauter; Hannah Schäfer; Jan-Ulrich Schlump; Steffen Syrbe; Charlotte Thiels; Regina Trollmann; Adelheid Wiemer-Kruel; Bernd Wilken; Bianca Zukunft; Adam Strzelczyk
Journal:  CNS Drugs       Date:  2021-07-17       Impact factor: 5.749

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.